Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Azimuth Capital reduced its Edwards Lifesciences stake by 9.9% in the second quarter, selling 22,092 shares and retaining 201,325 shares valued at approximately $18.2 million. Institutional investors collectively own 79.46% of the company.
• Edwards reported quarterly EPS of $0.78, exceeding the $0.74 analyst consensus, while revenue rose 13.6% year over year to $1.74 billion. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• Analyst sentiment remains favorable, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27 versus the reported share price of about $90.

Azimuth Capital Investment Management LLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 201,325 shares of the medical research company's stock after selling 22,092 shares during the period. Azimuth Capital Investment Management LLC's holdings in Edwards Lifesciences were worth $18,212,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the first quarter worth $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter worth $26,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.2%

Shares of Edwards Lifesciences stock opened at $90.00 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The firm has a market capitalization of $51.82 billion, a PE ratio of 51.72, a P/E/G ratio of 2.36 and a beta of 0.85. The firm's 50-day moving average price is $89.73 and its 200 day moving average price is $85.49.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. The business's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EW shares. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. UBS Group began coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Finally, Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company's stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,045 shares of company stock valued at $457,749 over the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source